T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials
Jiahe Zhao, Ayrton Bangolo, Lili Zhang, Martin Gutierrez, Miguel Gonzalez-Velez · 2026
Read T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials by Jiahe Zhao, Ayrton Bangolo, Lili Zhang, Martin Gutierrez, Miguel Gonzalez-Velez (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13582393.txt.
Description
Jiahe Zhao and colleagues surveyed clinical trials of T-cell redirecting therapies for lung cancer in 2026. Lung cancer still causes more cancer deaths than any other cancer worldwide. Checkpoint inhibitor drugs changed care, yet many tumours resist them from the start or later, and some tumour types respond poorly, leaving a clear unmet need.
Trials of therapies that steer T cells onto cancer cells are reviewed in full. Combinations with checkpoint inhibitors, antibody-drug conjugates, and ready-made or innate immune cells are judged the most promising route to lasting benefit. The authors expect progress toward late-stage trials, better patient selection by biomarkers, and larger-scale manufacturing of shared cell products.
Catalog record
| CREATOR | Jiahe Zhao, Ayrton Bangolo, Lili Zhang, Martin Gutierrez, Miguel Gonzalez-Velez |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |